Table 1 Baseline characteristics
Variable | RIPC (n = 45) | SHAM (n = 47) | p value |
|---|---|---|---|
Age, years (SD) | 67 (± 9) | 66 (± 10) | 0.577 |
Male, n (%) | 36 (80) | 32 (68) | 0.288 |
BMI, kg/m2 (SD) | 26.3 (± 6.4) | 26.5 (± 6.7) | 0.840 |
ASA 2, n (%) | 18 (40) | 19 (40) | 1 |
ASA 3, n (%) | 20 (44) | 22 (47) | 0.986 |
ASA 4, n (%) | 7 (16) | 6 (13) | 0.933 |
ACEI or ARB, n (%) | 21 (47) | 30 (64) | 0.148 |
Calcium channel blockers, n (%) | 9 (20) | 17 (37) | 0.135 |
Beta-blockers, n (%) | 11 (24) | 19 (40) | 0.158 |
Statins, n (%) | 13 (29) | 14 (30) | 1 |
Diabetes, n (%) | 5 (11) | 8 (17) | 0.607 |
Myocardial infarction, n (%) | 8 (18) | 3 (6) | 0.172 |
Stroke, n (%) | 10 (22) | 12 (26) | 0.899 |
Smoker (current or ex-smoker), n (%) | 40 (89) | 42 (89) | 1 |
MAP, mmHg (SD) | 99 (± 12) | 100 (± 11) | 0.678 |
Heart rate, bpm (SD) | 66 (± 9) | 67 (± 11) | 0.754 |
Cholesterol, mmol/L (IQR) | 5.0 (4.2–5.7) | 5.0 (3.9–5.6) | 0.793 |
LDL, mmol/L (IQR) | 3.4 (8.1–10.4) | 3.3 (2.5–3.8) | 0.500 |
HDL, mmol/L (IQR) | 1.1 (0.9–1.4) | 1.1 (1.0–1.3) | 0.311 |
Triglycerides, mmol/L (IQR) | 1.6 (1.3–1.8) | 1.5 (1.2–2.0) | 0.787 |
Administration of propofol, n (%) | 19 (42) | 26 (55) | 0.295 |
Duration of surgery, min (IQR) | 108 (89–135) | 112 (84–156) | 0.827 |